February 1, 2021

Good responses to lenvatinib were observed in patients with hepatocellular carcinoma who maintained a high relative dose intensity of 75% or greater.

Delivering the right treatment to the right patient with an eye toward tumor characteristics and gene alterations is at the heart of precision medicine. In this issue, we explore ongoing efforts to achieve precision medicine across disease settings.

Therapies targeting oncogenesis and the tumor microenvironment are increasingly replacing chemotherapies as first-line treatments for non–small cell lung cancer.

A tumor-agnostic approach in which treatment is developed based on a tumor’s genetic and molecular features without regard to the cancer type or primary tumor location in the body, is the focus of the National Cancer Institute -MATCH trial.

The treatment landscape of genitourinary malignancies has seen tremendous growth in the last decade with advancements in prostate, bladder, and urothelial cancers.

Patient-reported outcomes outcomes from the Check-Mate 743 trial demonstrated improved symptom burden and maintained overall health status with the use of nivolumab/ipilimumab over chemotherapy, in patients with unresectable malignant pleural mesothelioma.

Although lenvatinib has shown antitumor effects in hepatocellular carcinoma, long-term safety data are lacking.